2024
Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella
Rommel K, Bonnet G, Bellumkonda L, Lansky A, Zhao D, Thompson J, Zhang Y, Redfors B, Lurz P, Granada J, Bharadwaj A, Basir M, O'Neill W, Burkhoff D. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella. Journal Of Cardiac Failure 2024, 30: 1244-1254. PMID: 39389734, DOI: 10.1016/j.cardfail.2024.08.001.Peer-Reviewed Original ResearchConceptsRight ventricular dysfunctionHigh-risk percutaneous coronary interventionVentricular dysfunctionAssociated with right ventricular dysfunctionTricuspid annular plane systolic excursionConcomitant right ventricular dysfunctionLower left ventricular ejection fractionUnfavorable long-term prognosisAnnular plane systolic excursionClinical outcomes of patientsAbsence of right ventricular dysfunctionImpella supportPredictor of 1-year mortalityMultivariate Cox regression analysisIncidence of hypotensive episodesEchocardiography core laboratorySevere RV dilatationBlood urea nitrogen levelsRV function assessmentVentricular ejection fractionOutcomes of patientsRates of in-hospital mortalityHigher blood urea nitrogen levelsLong-term prognosisProportion of patientsClinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI
Abu-Much A, Grines C, Chen S, Batchelor W, Zhao D, Falah B, Maini A, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Zhang Y, Zhou Z, Baron S, Lansky A, Basir M, O'Neill W, Cohen D. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI. International Journal Of Cardiology 2024, 417: 132555. PMID: 39270940, DOI: 10.1016/j.ijcard.2024.132555.Peer-Reviewed Original ResearchLower left ventricular ejection fractionMitral valve regurgitationPercutaneous coronary interventionHigh-risk PCISevere MRHigh-risk percutaneous coronary interventionMR severityPCI-related complicationsValve regurgitationIII studiesHeart failureAssociated with worse outcomesPrevalence of heart failurePresence of severe MRLower body mass indexVentricular ejection fractionStatistical significanceHigh-risk PCI patientsBody mass indexTrace MREjection fractionModerate MRClinical outcomesMild MRWorse outcomesMechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightSurveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry
Khush K, Hall S, Kao A, Raval N, Dhingra R, Shah P, Bellumkonda L, Ravichandran A, Van Bakel A, Uriel N, Patel S, Pinney S, DePasquale E, Baran D, Pinney K, Oreschak K, Kobulnik J, Shen L, Teuteberg J. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. The Journal Of Heart And Lung Transplantation 2024, 43: 1409-1421. PMID: 38759766, DOI: 10.1016/j.healun.2024.05.003.Peer-Reviewed Original ResearchAcute cellular rejectionIncidence of acute cellular rejectionBiopsy rateGene expression profilesNon-invasive testsMolecular testingDd-cfDNACellular rejectionGraft dysfunctionHeart transplantationFollow-up testing ratesIncidence of graft dysfunctionLow biopsy rateFollow-up biopsiesPositive likelihood ratioNon-invasive surveillanceBiopsy dataClinical decision-makingExcellent survivalOutcomes RegistryFollow-upLow incidenceBiopsyPositive groupDual testingHigh- versus low-gradient aortic stenosis: Is our evaluation limited by aorto-mitral angle on cardiovascular CT?
See C, Kim Y, Park J, Wang Y, Reinhardt S, Shkolnik E, Faridi K, Lombo B, Bellumkonda L, McNamara R, Sugeng L, Hur D. High- versus low-gradient aortic stenosis: Is our evaluation limited by aorto-mitral angle on cardiovascular CT? International Journal Of Cardiology 2024, 409: 132174. PMID: 38754590, DOI: 10.1016/j.ijcard.2024.132174.Peer-Reviewed Original ResearchNormal-flow low-gradientAortic valve areaTranscatheter AV replacementParadoxical low-flow low-gradientCardiovascular CTTransthoracic echocardiogramCalcium scoreAS patientsDiagnosis of severe ASLow-gradient aortic stenosisHG-AS patientsLG-AS patientsLow-flow low-gradientAorto-mitral angleAortic valve (AV) stenosisLG-ASPLFLG-ASAV replacementSevere ASConsecutive patientsAortic stenosisValve areaAS phenotypeClinical managementEchocardiogramThree-dimensional (3D) Right Ventricular Surface Strain Computed From 3D Echocardiography Correlates With RVEF and Reveals Differences in Deformation Based on Severity of Pulmonary Arterial Hypertension Symptoms
Oakland H, Bellumkonda L, Sugeng L, Joseph P, Izzi D, Zalik F, McCabe S, Raza A, Amendola R, Heerdt P, Singh I, Hunter K. Three-dimensional (3D) Right Ventricular Surface Strain Computed From 3D Echocardiography Correlates With RVEF and Reveals Differences in Deformation Based on Severity of Pulmonary Arterial Hypertension Symptoms. 2024, a7381-a7381. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7381.Peer-Reviewed Original Research(1118) Impact of Induction Therapy on Gene Expression Profiling and Donor Derived Cell Free DNA
Dhingra R, Bellumkonda L, Vaidya A, Chen L, Jawaid A, Czinn E, Pinney K, Wang S, Patel S, Jenkins L, DePasquale E, Guha A, Uriel N. (1118) Impact of Induction Therapy on Gene Expression Profiling and Donor Derived Cell Free DNA. The Journal Of Heart And Lung Transplantation 2024, 43: s519-s520. DOI: 10.1016/j.healun.2024.02.735.Peer-Reviewed Original ResearchSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original ResearchConceptsDiuretic resistanceCardiorenal syndromeHeart failureLoop diureticsDiuretic withdrawalHigh-dose loop diureticsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideGrowth differentiation factor 15Carbohydrate antigen 125Differentiation factor 15Sodium removalRandomized controlled studyCardiorenal parametersDiuretic doseSoluble ST2Natriuretic peptideMedian timeDiuretic responseKidney injuryPeritoneal membraneElectrolyte handlingKidney functionDiureticsInterleukin-6
2023
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI
Abu-Much A, Grines C, Batchelor W, Maini A, Zhang Y, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Li Y, Baron S, Lansky A, Basir M, Cohen D, O'Neill W. Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI. American Heart Journal 2023, 269: 139-148. PMID: 38151142, DOI: 10.1016/j.ahj.2023.12.015.Peer-Reviewed Original ResearchBaseline LV ejection fractionLV ejection fractionPercutaneous coronary interventionPCI-related complicationsLV dysfunctionEjection fractionLV functionLeft main percutaneous coronary interventionHigh-risk percutaneous coronary interventionHigh-risk PCI patientsImmediate percutaneous coronary interventionMain percutaneous coronary interventionModerate LV dysfunctionSevere LV dysfunctionVentricular systolic dysfunctionVentricular ejection fractionCoronary complicationsLVEF groupMACCE rateCerebrovascular eventsPCI patientsSystolic dysfunctionCoronary interventionIII studyMyocardial infarctionEmpagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field M, Wiederin D, Butler J, Collins S, Turner J, Wilson F, Inzucchi S, Wilcox C, Ellison D, Testani J. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. Journal Of The American Society Of Nephrology 2023, 35: 189-201. PMID: 38073038, PMCID: PMC10843196, DOI: 10.1681/asn.0000000000000269.Peer-Reviewed Original ResearchAssessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement
Denfeld Q, Jha S, Fung E, Jaarsma T, Maurer M, Reeves G, Afilalo J, Beerli N, Bellumkonda L, De Geest S, Gorodeski E, Joyce E, Kobashigawa J, Mauthner O, McDonagh J, Uchmanowicz I, Dickson V, Lindenfeld J, Macdonald P. Assessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement. The Journal Of Heart And Lung Transplantation 2023, 43: 1-27. PMID: 38099896, DOI: 10.1016/j.healun.2023.09.013.Peer-Reviewed Original ResearchAdvanced heart failureDefinition of frailtyHeart failureConsensus statementOverview of frailtyAssessment of frailtyMeasurement of frailtyCritical evidence gapsHF cliniciansFrailty assessmentGeriatric conditionsNonsurgical interventionsClinical practiceEvidence gapsFrailtyPsychological impairmentPhysical performanceClinical implementationPatientsInternational SocietyComorbiditiesPrevious studiesSarcopeniaAssessmentFailureVariation in Reader-Reported Severity of Paradoxical Low-Flow Low-Gradient Aortic Stenosis
Shah N, Sugeng L, Zhang Z, Wang K, McNamara R, Agarwal V, Hur D, Lombo B, Bellumkonda L, Mankbadi M, Basem Dajani A, Forrest J, Krumholz H, Reinhardt S, Velazquez E, Faridi K. Variation in Reader-Reported Severity of Paradoxical Low-Flow Low-Gradient Aortic Stenosis. Journal Of The American Society Of Echocardiography 2023, 37: 466-467. PMID: 37995937, DOI: 10.1016/j.echo.2023.11.014.Peer-Reviewed Original ResearchRole of ascorbic acid in cardiac allograft vasculopathy
Chang A, Martin K, Colvin M, Bellumkonda L. Role of ascorbic acid in cardiac allograft vasculopathy. Clinical Transplantation 2023, 37: e15153. PMID: 37792313, DOI: 10.1111/ctr.15153.Peer-Reviewed Original ResearchConceptsCardiac allograft vasculopathySmooth muscle cell apoptosisAllograft vasculopathyDisease processMuscle cell apoptosisSignificant long-term morbidityCell apoptosisProgressive fibroproliferative diseasePost-transplant carePost-transplant managementLong-term morbiditySmall clinical trialsChallenging disease processVascular smooth muscle cell apoptosisHeart transplantationCAV progressionEndothelial dysfunctionRapamycin inhibitorsClinical trialsIntimal thickeningPrevents developmentInterferon γRodent modelsIntimal hyperplasiaMTOR inhibitorsTCT-214 Right Ventricular Function in Patients Undergoing Impella-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study
Rommel K, Bonnet G, Bellumkonda L, Zhang Y, Lansky A, Redfors B, Granada J, Bharadwaj A, Basir B, Patel R, O’Neill W, Burkhoff D. TCT-214 Right Ventricular Function in Patients Undergoing Impella-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study. Journal Of The American College Of Cardiology 2023, 82: b82-b83. DOI: 10.1016/j.jacc.2023.09.221.Peer-Reviewed Original ResearchDual organ transplantation: when heart alone is not enough
Nuqali A, Bellumkonda L. Dual organ transplantation: when heart alone is not enough. Current Opinion In Organ Transplantation 2023, 28: 370-375. PMID: 37582057, DOI: 10.1097/mot.0000000000001093.Peer-Reviewed Original ResearchConceptsDual-organ transplantationOrgan transplantationPatient selectionBetter long-term outcomesDual organ transplantsSingle organ transplantationTransplant center experienceLong-term outcomesAdvanced disease processLong-term managementPosttransplant outcomesCenter experienceImmunological advantageOrgan transplantsDisease processPartial toleranceSecond organPatientsTransplantationLack of standardizationOutcomesOrgansUrgent needTransplantImpella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. Cardiovascular Revascularization Medicine 2023, 53: s126. DOI: 10.1016/j.carrev.2023.05.290.Peer-Reviewed Original ResearchShort-Term Outcomes Among Aortic Valve Stenosis Patients Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention
Velagapudi P, Abu-Much A, Bellumkonda L, Maini A, Redfors B, Lansky A, Li Y, Grines C, Batchelor W, O'Neill W, Cohen D. Short-Term Outcomes Among Aortic Valve Stenosis Patients Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention. Cardiovascular Revascularization Medicine 2023, 53: s110. DOI: 10.1016/j.carrev.2023.05.253.Peer-Reviewed Original ResearchIntra-Aortic Balloon Pump: Uncovering Myths and Misconceptions
Isath A, Naami E, Fried J, Bellumkonda L, Naidu S, Tang W, Sharma S, Jneid H, Krittanawong C. Intra-Aortic Balloon Pump: Uncovering Myths and Misconceptions. Current Problems In Cardiology 2023, 48: 101806. PMID: 37209795, DOI: 10.1016/j.cpcardiol.2023.101806.Peer-Reviewed Original ResearchThe importance of forward flow and venous congestion in diuretic response in acute heart failure: Insights from the ESCAPE trial
Eder M, Griffin M, Moreno-Villagomez J, Bellumkonda L, Maulion C, Asher J, Wilson F, Cox Z, Ivey-Miranda J, Rao V, Butler J, Borlaug B, McCallum W, Ramos-Mastache D, Testani J. The importance of forward flow and venous congestion in diuretic response in acute heart failure: Insights from the ESCAPE trial. International Journal Of Cardiology 2023, 381: 57-61. PMID: 37023862, DOI: 10.1016/j.ijcard.2023.04.002.Peer-Reviewed Original ResearchConceptsRight atrial pressureDiuretic efficiencyRight atrial areaDiuretic responseVenous congestionHeart failureCardio-renal interactionsLoop diuretic doseAcute heart failureRenal perfusion pressureLow cardiac outputMean arterial pressureRight ventricular systolicCongestive heart failureVentricular ejection fractionNet fluid outputForward flowDiuretic doseDiuretic resistanceTTE parametersCardiac indexVentricular systolicArterial pressureAtrial pressureEjection fractionImpact of Steroid Withdrawal on Gene Expression Profiling, Donor Derived Cell-Free DNA, and Clinical Outcomes in the SHORE Registry
Bellumkonda L, Uriel N, Fu Y, Shen L, Qu K, Baran D. Impact of Steroid Withdrawal on Gene Expression Profiling, Donor Derived Cell-Free DNA, and Clinical Outcomes in the SHORE Registry. The Journal Of Heart And Lung Transplantation 2023, 42: s494. DOI: 10.1016/j.healun.2023.02.1362.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDd-cfDNA levelsCardiac allograft vasculopathySteroid withdrawalGraft dysfunctionCell-free DNAGEP scoreGene expression profilingMulti-organ transplant recipientsNovo donor-specific antibodiesDe novo DSAPost-heart transplantSteroid withdrawal groupDonor-specific antibodiesAllograft vasculopathySteroid doseCause mortalityTransplant recipientsMethods PatientsSteroid treatmentComplete discontinuationPropensity matchingClinical outcomesOutcomes RegistryWithdrawal group